comparemela.com

Latest Breaking News On - Hansoh pharma - Page 8 : comparemela.com

GSK Inks License Deal With China s Hansoh Pharma For HS-20093; To Pay Up To $1 7 Bln

GSK Inks License Deal With China s Hansoh Pharma For HS-20093; To Pay Up To $1 7 Bln
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hong kongCity ofUnited kingdomHansoh pharmaStefan klotterHart scott rodino actLassen sie

GSK : enters exclusive license agreement with Hansoh for HS-20093 -December 20, 2023 at 07:42 am EST

Hansoh s HS-20093 builds on GSK s oncology portfolio of clinical-stage antibody-drug conjugates, following earlier agreement for Hansoh s HS-20089 focused on gynaecologic cancers .

United statesHong kongEliza sunHansoh pharmaHesham abdullahAmerican society of clinical oncologyGlobal head oncologyClinical oncologyExecutive directorHart scott rodino actAnnual report

GSK strikes deal with Hansoh Pharma worth up to $1 7B for ADC asset

The exclusive license agreement will give GSK rights to Hansoh’s HS-20093, a B7-H3 targeted ADC that’s being investigated in several cancers.

Hesham abdullahHansoh pharmaEliza sunBristol myers squibbChina based hansoh pharmaMyers squibb

GSK enters exclusive license agreement with Hansoh for HS-20093 | GSK

- Hansoh s HS-20093 builds on GSK s oncology portfolio of clinical-stage antibody-drug conjugates, following earlier agreement for Hansoh s HS-20089 focused on gynaecologic cancers - HS-20093 has.

United statesHong kongHesham abdullahHansoh pharmaEliza sunAmerican society of clinical oncologyGlobal head oncologyClinical oncologyExecutive directorHart scott rodino actAnnual report

GSK Expands Again in Cancer, Paying Hansoh $185M for Another ADC

GSK gains rights to a Hansoh Pharma antibody drug conjugate that targets a protein abundant on lung cancer cells and other types of solid tumors. The pharmaceutical giant plans to start its own slate of clinical trials with this ADC in 2024.

United statesHong kongSouth koreaDaiichi sankyoHesham abdullahHansoh pharmaBristol myers squibbAmerican society of clinical oncologyAmerican societyOrum therapeuticsWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan francisco

vimarsana © 2020. All Rights Reserved.